Kornimate/medical-research-clean huggingface dataset:
a randomized trial of imaging selection modalities for stroke thrombectomy (no-select)

Conditions: Stroke, Ischemic; Stroke, Acute

Summary: several studies suggest that advanced multi-modal imaging with ctp should be used to screen late time window stroke patients for thrombectomy. however, ncct is more accessible when comparing with ctp. it is unclear whether the ncct-based aspects can be used as an imaging criterion to screen patients for thrombectomy. the newly published mr clean-late and tension trials used ncct or cta, but still relied on aspects scores to evaluate and select patients for endovascular therapy. however, different trials have different time windows. the aim of this trial was to assess the clinical outcomes of stroke patients with anterior large vessel occlusion who selected by simple imaging (ncct) comparing via standard imaging screening strategy (ctp/mri). the hypothesis is that simple imaging is non-inferior to standard imaging selection strategy in terms of achieving favorable outcomes.


Eligibility criteria:
inclusion criteria: 1. aged 18 years or older; 2. the interval time from last known well to hospital arrival is within 24 hours; 3. acute stroke confirmed by clinical symptoms or imaging examination; 4. field assessment stroke triage for emergency destination (fast ed) ≥4; 5. written informed consent is obtained from patients and/or their legal representatives. exclusion criteria: 1. allergy to radiographic contrast agents, or nitinol devices; 2. currently pregnant or lactating (women patients); 3. arterial tortuosity and/or other arterial disease that would prevent the device from reaching the target vessel; 4. preexisting neurological or psychiatric disease that would confound the neurological functional evaluations; 5. multiple vessel occlusion (e.g., bilateral anterior circulation, or occlusion of both anterior and posterior circulation); 6. brain tumors with mass effect (except meningiomas) that are radiographically pleasant; 7. intracranial aneurysm, arteriovenous malformation; 8. any terminal illness with life expectancy less than 6 months; 9. unlikely to be available for 90-day follow-up.

Keywords: endovascular treatment large vessel occlusion acute ischemic stroke computed tomography perfusion non-contrast computed tomography alberta stroke program early ct score
vet-harts pilot intervention for veterans with coronary heart disease

Conditions: Heart Disease

Summary: the purpose of this research study is to survey patients to learn about their beliefs and behaviors related to the management of heart disease and to discuss options for making healthy lifestyle changes. from the information the investigators get from patients, the investigators hope to develop better methods for taking care of patients who have heart disease.

coronary heart disease (chd) is a significant health threat among veterans. compared to their civilian counterparts, veterans experience greater disability, reinfarction, and mortality following myocardial infarction (mi) and other acute coronary syndromes (acs). high rates of hypertension, diabetes, and cardiac risk behaviors (e.g., smoking) and low socioeconomic status (ses) further increase veterans' chd-related morbidity and mortality. the proposed pilot project will establish the feasibility of a telehealth nursing intervention for veterans with chd who are recovering from mi/acs. the veterans heart attack representations telehealth (vet-hart) intervention is designed to promote adaptive conceptual change in veterans' beliefs (common sense models or representations) about chd etiology and self-management and facilitate health behavior changes (e.g., smoking cessation, medication adherence, diet management, and increased physical activity). the long-term goal of this research program is to improve veterans' quality of life (qol) and reduce their chd-related morbidity/mortality. the proposed project is the requisite next step in attaining that goal.

Eligibility criteria:
inclusion criteria: * admission to an inpatient medicine unit for mi, acs, and coronary angiography * age exclusion criteria: * altered mental status * language barriers * dementia or cognitive impairment * diagnostic study * resident in long-term care facility prior to the present admission * planned discharge to a skilled or intermediate care facility or hospice * lack of access to a functioning phone

Keywords: coronary heart disease (chd) myocardial infarction (mi) acute coronary syndromes (acs)
a study to compare the pharmacokinetics and safety of a fixed dose combination of fimasartan/amlodipine/rosuvastatin

Conditions: Hypertension; Hyperlipidemia

Summary: a open-label, randomized, single-dose, 2x2 crossover study to compare the pharmacokinetics and safety between a fixed dose combination of fimasartan/amlodipine/rosuvastatin versus co-administration of a fixed dose combination of fimasartan/amlodipine and rosuvastatin in healthy male subjects.


Eligibility criteria:
inclusion criteria: * a healthy male subject, aged 19- 50 years exclusion criteria: * history of clinically significant hypersensitivity to study drug, any other drug * hypotension or hypertension * active liver disease * history of gastrointestinal disease * history of excessive alcohol abuse * participation in any other study within 3 months
analysis before and after covid 19

Conditions: Cost of ICU

Summary: in our study, we aimed to compare the average length of stay, death rates and costs of intensive care patients in october-november-december 2019 (before covid 19) and october-november-december 2020 (during covid 19).


Eligibility criteria:
inclusion criteria: * above 18 years old * all patients in intensive care unit in last three months of 2019 * all sars-cov2 patients in intensive care unit in last three months of 2020 exclusion criteria: * under 18 years old
effect of acute protein supplementation in diabetic patients

Conditions: Diabetes Mellitus Type 2

Summary: the goal of this trial is to test the effect of house cricket (acheta domesticus) preload on glycemic response in diabetic patients. the main question\[s\] it aims to answer are: whether house cricket powder could lower blood glucose spike and stimulate higher insulin response. participants will consume either house cricket powder, whey protein isolate or placebo which will be mixed with a chicken-flavored soup. participants fingers will be pricked for up to 2 hours. researcher will compare house cricket powder with placebo to see if the glycemic response is better in house cricket supplemented group. researcher will compare house cricket powder with whey protein isolate to see if both supplement induce comparable glycemic response.

participants blood will be collected at 8 time points: baseline 20 minutes after pre load 15 minutes after oral glucose tolerance test (ogtt) 30 minutes after ogtt 45 minutes after ogtt 60 minutes after ogtt 90 minutes after ogtt 120 minutes after ogtt

Eligibility criteria:
inclusion criteria: * suffering from type 2 diabetes mellitus (hba1c \> 6.5%) * consume metformin for at least 6 months exclusion criteria: * consume other type of anti-diabetic drugs * presenting any food allergy * recent surgery or infections that may affect oral glucose tolerance test * consume other drugs that may affect oral glucose tolerance test * not consuming any anti-diabetic drugs * pre-diabetes (hba1c 5.7 - 6.4%)
pharmacological and mechanical support approaches in the management of acute heart failure in the regional network model for the management of cardiogenic shock

Conditions: Cardiogenic Shock; Acute Coronary Event

Summary: the goal of this observational study is to understand and describe the epidemiology of cardiogenic shock in emilia romagna with a specific focus on outcome stratified by aetiologies, sex and age. the main outcomes are: * incidence of cardiogenic shock (cs) over the total cicu admissions, cs-related in-hospital mortality and length of hospitalization, stratified by aetiologies, sex and age * epidemiology of patients admitted with cs, regarding age, gender, etiology and modality of presentation (acute or acute on chronic), echocardiographic and haemodynamic data, treatment strategy with inotropes and/or short-term mcs, cardiac arrest. this is an observational study without intervention. patients will be treated according to current clinical practice, according to physician judgment and data sheets of each drug used according to clinical practice.

this is a multicenter observational study with both a retrospective and a prospective cohort. study population will include all consecutive patients diagnosed with cardiogenic shock and admitted to the cardiac intensive care unit of the participating centers. for the patients enrolled at irccs azienda ospedaliera-universitaria di bologna this study will involve a collaboration with uo cardiologia. for the retrospective cohort, patients will be selected based on icd9 discharge codes and included if they fulfill inclusion criteria after review of hospital charts. the retrospective cohort will serve as a historical comparison regarding epidemiology, treatment strategies and survival. incidence and workload burden of cicu will be studied comparing the number of cs patients and the total number of admissions in the study period.

Eligibility criteria:
inclusion criteria: * adult patients (≥18 years old) admitted to a participating cicu with suspected cs of stage from c to e according to scai (society of cardiovascular intervention)classification of cardiogenic shock. * signed informed consent. exclusion criteria: * cs following cardiac surgery (post-cardiotomy), ● significant polytrauma or neurological injury.
a trial comparing wound drainage and post-operative complications with and without the use of evicel™ fibrin sealant in thyroidectomy

Conditions: Thyroid Neoplasm; Goiter

Summary: primary objectives * to compare the amount of post-operative wound drainage between the group of patients in which evicel™ spray is utilized (arm a), and the group of patients in which an evicel™ placebo is utilized (arm b). * to compare the length of time to drain removal between arm a and arm b. secondary objectives * to compare the incident or rates of seroma, hematoma, and post-operative edema between the two groups. * to compare the reported pain experienced in each group at selected time points using a standard numerical rating scale (nrs). * to compare the length of hospital stay between the two groups of patients.


Eligibility criteria:
inclusion criteria * patients must have an initial diagnosis of thyroid neoplasmcarcinoma or goiter that requires total or hemithyroidectomy. * patients must have an ecog performance status of 0-2 * laboratory values must be within the following ranges: * platelet count \> 100 k/mm3 * hemoglobin \> 10.0 g/dl * wbcs \> 3.0 k/mm3 * total bilirubin \< 2.6 * serum creatinine \< 2.0 * ptt and pt/inr within institutional normal limits * patients must sign informed consent for study participation exclusion criteria * evidence of distant metastasis of thyroid carcinoma * recurrent thyroid cancer * prior thyroid surgery or surgery to the neck. * patients with diagnosed coagulation disorders * prior irradiation to the neck area * prior chemotherapy for the current diagnosis * patients on therapeutic warfarin * patients with psychological or cognitive issues that, in the opinion of the investigator, will make them unable to adequately report pain levels * patients in an immune deficient state

Keywords: evicel, fibrin sealant, thyroidectomy
a novel skin barrier protectant for acute radiodermatitis

Conditions: Radiodermatitis; Radiation Toxicity; Radiation Dermatitis; Skin Diseases; Head and Neck Cancer

Summary: acute radiodermatitis (ard) is a distressing and painful skin reaction that occurs in 95% of the patients undergoing radiotherapy (rt). to date, there is still no general approved guideline for the prevention and management of acute radiodermatitis. the 3m™ cavilon™ advanced skin protectant is a novel skin barrier protectant that acts as a physical barrier against abrasion, moisture, and irritants. moreover, it enables an environment for wound healing. the aim of this study is to evaluate the effectiveness of 3m™ cavilon™ advanced skin protectant in the prevention and management of ard in patients with head and neck cancer.


Eligibility criteria:
inclusion criteria: * diagnosis of head and neck squamous cell carcinomas (hnscc) starting in the lip, salivary gland, oral cavity (mouth), nasal cavity (inside the nose), paranasal sinuses, pharynx, or larynx. * scheduled for bilateral neck radiotherapy (\>60 gy) with or without concomitant chemotherapy either as primary or as post-operative treatment to the head and neck region * age ≥ 18 years * able to comply to the study protocol * able to sign written informed consent * signed written informed consent exclusion criteria: * previous irradiation to the head and/or neck region * metastatic disease * patients with pre-existing skin rash, ulceration or open wound in the treatment area * patients with known allergic and other systemic skin diseases even when not directly affecting irradiated fields * substance abuse patients or patients with medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator * any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator * patients using high doses of non-steroidal anti-inflammatory drugs * patients allergic to the ingredients of the 3m™ cavilon™ advanced skin protectant
efficacy and safety of endobiliary radiofrequency ablation by using a novel rf catheter (elra®) on maintaining the patency of endobiliary metal drainage in patients with malignant biliary strictures : a double-arm comparable study

Conditions: Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer

Summary: malignant obstructive jaundice is a common complication of advanced stage cholangiocarcinoma, gallbladder cancer, and pancreatic cancer. in biliary stricture by malignancy, biliary drainage with placement of self-expanding metal stent (sems) for palliation is the therapy of choice in these patients. when compared to plastic stents, sems present a significantly decreased risk of recurrent biliary obstruction. sems are also more cost-effective than plastic stents in patients with a life expectancy of longer than 4 months. however, despite their numerous benefits, sems become occluded in up to 50 % of patients in the first 6-8 months. radiofrequency ablation (rfa) has been used to treat malignancies of the liver since the early 1990s. other studies have investigated its role in diseases of the colon and esophagus. more recently, this technique has been recognized for its potential in palliative treatment of malignant biliary strictures. rfa uses a high-frequency alternating current to generate heat and achieve coagulative necrosis when in contact with tissue. within the bile duct, rfa appears to be safe and may result in decreased benign epithelial hyperplasia and tumor ingrowth. however, rfa along with placement of sems has not been well studied. on the other hand, newly developed rfa catheter (elra®) showed the feasibility and safety in south korea, recently. the purpose of this study was to investigate the efficacy and safety of endobiliary rfa by using a novel rf catheter (elra®) on maintaining the patency of endobiliary metal drainage in patients with malignant biliary strictures.


Eligibility criteria:
inclusion criteria: * pathologically confirmed malignant biliary obstruction or clinically defined malignant biliary obstruction * older than 19 years old * life expectancy \> 3 months * inoperable case due to advanced stage or comorbidity * informed consent exclusion criteria: * inadequate case for ercp * inadequate coagulation (platelet count \ 1.5) * abnormal biliary tract system due to previous operation * failed endoscopic approach to duodenum or biliary tract * pregnancy * no signed informed consent

Keywords: cholangiocarcinoma, radiofrequency ablation, metal stent
non-invasive versus invasive blood pressure measurement in the morbidly obese parturient with severe preeclampsia

Conditions: Pre-Eclampsia; Morbid Obesity; Parturient; Blood Pressure

Summary: the study will compare agreement of invasive blood pressure measurements with non-invasive blood pressure measurements measured with a conical blood pressure and large standard upper arm rectangular cuff in morbidly obese severely hypertensive (systolic blood pressure \> 160 mmhg) parturients.

a morbidly obese \[body mass index (bmi) ≥ 40 kg/m2\] pregnant woman is at singular risk for all the complications of pregnancy, most notably preeclampsia (pe). furthermore a woman who is already chronically hypertensive is likely to develop superimposed pe . uncontrolled systolic hypertension in pregnancy prompts placental abruption, hemorrhagic stroke, and systolic or diastolic heart failure. accurate blood pressure measurement is therefore a prerequisite to controlling dangerously high systolic blood pressure (sbp) to enable labor and delivery to be conducted safely in association with pe. precise sbp measurement is also a precondition for clinically testing hypotheses concerning the existence of druggable targets that will allow prolongation of pregnancy in the face of severe pe and /or intra-uterine growth restriction (iugr) remote from term. oscillometric noninvasive blood pressure (nibp) measurement is the customary standard blood pressure monitoring method most often used in the labor suite and obstetric operating room today. for this purpose a rectangular, cylindrical blood pressure (bp) cuff placed on the upper arm is connected to an oscillometric blood pressure device. yet inaccuracies related to the fact that oscillometric nibp devices under-read high sbp relative to ibp measurements have been recognized as a potential source of maternal morbidity for years. the study will compare ibp readings obtained from morbidly obese, severely hypertensive (sbp \> 160 mm hg) parturients with nibp consecutively measured with new innovative conical ultracheck curve bp cuffs and large standard upper arm rectangular cylindrical bp cuffs.

Eligibility criteria:
inclusion criteria: * written, signed and dated informed consent * ≥ 18 years of age * bmi \>40 kg/m2 * has a clinically indicated radial artery line already in situ or who agree to placement of an arterial line * systolic blood pressure \>160 mm hg * gestational age greater than or equal to 24 weeks * parturients admitted for induction of labor exclusion criteria: * parturients admitted in labor
optimization of treatment and management of schizophrenia in europe (optimise): substudy site copenhagen

Conditions: Schizophrenia; Schizophreniform Disorder; Schizoaffective Disorder

Summary: the investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) d2 receptors, brain structure, brain function, and information processing to each other and to psychopathology. additionally, the investigators want to examine the influence of d2 receptor blockade on these disturbances. the investigators expect disturbances in the dopaminergic system at baseline to correlate with specific structural and functional changes and with disruption in information processing as measured with psychophysiological and neurocognitive methods - and investigators expect d2 receptor blockade to reverse some of the functional and cognitive impairments. the investigators do not expect any effect of treatment on brain structure.

the study is designed as a 4 week case-control follow-up study of 90 fe pt. with scz and 90 controls matched with regard to age, gender, and parental socio-economic status. all subjects will be examined with a diagnostic interview (scan, schedule for clinical assessment in neuropsychiatry), medical and family history, and physical examination before inclusion. at baseline subjects will be examined with single photon emission computed tomography (spect), mri, fmri, psychophysiology, neurocognition. in addition, they will be screened for drugs, genetic testing, and ecg. patients will further be examined with clinical validated rating scales to measure psychopathology, subjective well-being, and side-effects. after a period of 4 weeks all assessments are repeated. during that period patients will be treated with amisulpride, while healthy controls will receive no treatment at all. efficacy of antipsychotic treatment will be evaluated after this initial period of 4 weeks. all subjects will be re-assessed in the same test battery as mentioned above, except for spect and fmri, after a period of 6, 12, and 24 months.

Eligibility criteria:
inclusion criteria: * schizophrenia, schizophreniform or schizoaffective disorder (dsm-iv) * age 18-40 years * written informed consent. exclusion criteria: * a time interval between the onset of positive symptoms (hallucinations and/or delusions) and study entry exceeding two years. * prior use of antipsychotic medication longer than an episode of two weeks in the previous year and/or 6 weeks lifetime. * intolerance to one of the drugs in this study. patients who are coercively treated at a psychiatric ward (based on a judicial ruling) * patients who are represented by a legal ward or under legal custody * the presence of one or more of the contraindications against any of the study drugs as mentioned in the spc texts * pregnancy, as determined through a pregnancy test, or lactation

Keywords: dopamine first episode reward cognition mri fmri ppi p300 p50 gating endophenotypes
comparison of critical flicker fusion versus automated visual fields in the detection of early glaucoma

Conditions: Glaucoma

Summary: the purpose of this study is to evaluate if critical flicker fusion is a more reliable method for detection of early glaucoma compared to automated visual fields in comparison to subjects without evidence of glaucoma or optic nerve disease.

our hypothesis is that critical flicker fusion (cff) is a more reliable method for detection of early glaucoma compared to automated visual fields in comparison to subjects without evidence of glaucoma or optic nerve disease. we aim to evaluate the structure of the optic nerve and compare it to results of visual fields and cff. the cff will also be correlated with intraocular pressure (iop) measurements to observe if it may be more closely related than visual fields. this may become an additional tool to detect glaucoma in those with unreliable visual fields or who are unable to perform a visual field from physical or mental limitations.

Eligibility criteria:
inclusion: * glaucoma suspects: * abnormal optic disc appearance with increased cup to disc ratio, or * increased intraocular pressure \>21 in either eye * control subjects: * normal appearing optic discs * normal intraocular pressure (\<21) exclusion: * other ocular pathology * history of seizures or epilepsy
multi-center, randomized trial of the pulsed dye laser for jorrp

Conditions: Recurrent Respiratory Papillomatosis

Summary: the purpose of this study is to determine whether the 585-nm pulse dye laser can decrease the time interval between surgeries and improve voice outcomes in children with severe rrp.


Eligibility criteria:
inclusion criteria: 1. immunocompetent children ages 1-12 with symptomatic jorrp requiring operative intervention 2. children who have historically required at least four surgeries in the year preceding enrollment to treat laryngeal jorrp exclusion criteria: 1. children who have required fewer than four procedures to treat laryngeal jorrp in the year prior to enrollment. 2. children who are currently receiving adjuvant therapies for jorrp including cidofovir, interferon, indole-3-carbinol or hsp-e7. 3. caregivers who are non-english speaking as the pvrqol instrument has been validated only in the english language. 4. children whose families do not sign an informed consent to enter into the study. 5. children whose families anticipate discontinuing care at a participating institution during the study period

Keywords: papilloma, papillomatosis, laser, laser surgery